ArticleThoracic research and practice2026
Endobronchial Ultrasonography (EBUS) with Lymph Node Aspiration: On-site Evaluation and Final Pathology Correlation.
Article in Thoracic research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRapid on-site evaluation (ROSE) during endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA) may improve sample adequacy and expedite clinical decision-making; however, its impact on diagnostic performance and concordance with final pathology remains unclear. MATERIAL AND
methodsWe retrospectively analyzed consecutive adult patients who underwent EBUS-TBNA between February 2023 and January 2024. ROSE adequacy, final diagnostic adequacy, and ROSE-final pathology concordance were calculated. Factors associated with these outcomes were assessed using logistic regression analysis.
resultsNinety-five patients (mean age 65±13.8 years; 62.2% male) and 203 targets were sampled with 683 aspirations (3.4±1.8 passes/station). Based on lymph node (LN) level ROSE sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 76.6%, 100.0%, 100.0%, 85.4%, and 90.1%, respectively. The adequacy rates were 89.7% for ROSE and 90.6% for final pathology, and the ROSE-final pathology concordance was 88.2%. Diagnostic discordance occurred in 11.8% of the nodes, most of which were related to limitations in tumor subtyping. A greater number of needle passes was positively associated with ROSE adequacy (
conclusionROSE during EBUS-TBNA yielded high sensitivity and overall accuracy, demonstrated strong sample adequacy, and showed substantial concordance with the final pathology. Optimizing the number of passes and considering LN size can enhance adequacy, and recognizing the limitations of cytological subtyping and potential observer variability is essential for multidisciplinary decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.